Updated CLIA Waiver Guidances Lack Details in Original Draft

By Allyson B. Mullen — In the midst of the government shutdown and with its accompanying lull in new FDA documents, we thought it would be a good time to update our readers on some guidances that were issued late last year.  Two such notable draft guidances were the, “Select Updates for Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices” (CLIA Waiver Guidance) and “Recommendations for Dual 510(k) and CLIA Waiver by Application Studies” (Dual Waiver Guidance).  CDRH issued draft versions of these guidance documents on November 29, 2017, and exactly one year later the Center reissued updated drafts of these guidance documents.  We blogged on the 2017 drafts here.  The overall requirements and framework of the guidances have not changed substantively since 2017. In a recent pre-submission meeting that we had with CDRH, the Center stated…

Read more detail on Recent Products Liability posts –

This entry was posted in Products Liability and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply